THERAPY DOSSIER · th-303ffd8ccc9d

Tn immunogen, anti-Tn vaccine, maternal immunisation

Biologic · Tn-antigen immunogen / anti-Tn carbohydrate vaccine; glycoconjugate cancer vaccine.

Evidence & regulatory context

Mechanism: Tn-antigen immunogen / anti-Tn carbohydrate vaccine; glycoconjugate cancer vaccine.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00003638 ↗PHASE3completed

Theratope (STn-KLH) Vaccine for Metastatic Breast Cancer

Breast Cancer

Enrolment: 950 · Results not recorded

NCT00030823 ↗NAcompleted

Heptavalent (incl. Tn) Antigen-KLH Conjugate Vaccine + QS21 in High-Risk Breast Cancer

Breast Cancer

Enrolment: 14 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32311698 ↗2020Reported benefit

Immunization with anti-Tn immunogen in maternal rats protects against hyperoxia-induced kidney injury in newborn offspring.

RatOtherSprague-DawleyFemale dams immunised; sex of pups not statedIntraperitoneal50 micrograms per doseMaternal immunisation before injury, at 8, 6, 4, 2 and 0 weeks before delivery

Model: Neonatal hyperoxia-induced kidney injury; pups reared for 2 weeks in room air or an 85 per cent oxygen-enriched atmosphere

Hyperoxia reduced body weight and caused tubular and glomerular injury with increased 8-hydroxy-2'-deoxyguanosine, NF-kappaB and collagen deposition. Maternal Tn immunisation reduced kidney injury and collagen deposition alongside lower 8-hydroxy-2'-deoxyguanosine and NF-kappaB expression.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…